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Abstract
A prospective cohort study including all new cases of methicillin-resistant Staphylococcus aureus (MRSA) colonization or infection in 64
Spanish hospitals during June 2003 was performed to investigate the epidemiology of MRSA in Spain. Only patients who yielded clinical
MRSA-positive samples were included. Epidemiological and clinical data for a total of 370 cases were collected. Genotyping was per-
formed using pulsed-ﬁeld gel electrophoresis and multilocus sequence typing. Panton–Valentine leukocidin genes and the staphylococcal
chromosomal cassette mec (SCCmec) were identiﬁed in representative isolates. MRSA was considered to be nosocomially acquired in
202 cases (55%), healthcare-associated (HCA) in 139 cases (38%), community-acquired (CA) in three cases, and of uncertain mode of
acquisition in 26 (7%) cases. The pooled population-based rate was 2.31 cases/100 000 population/month, and the pooled nosocomial
rate was 0.21 cases/1000 hospital stays (20.2% of S. aureus). Peripheral vascular disease, respiratory tract infections, catheter infections,
bloodstream infections and crude mortality were more frequent among HCA cases, whereas neoplasia and urinary tract infections were
more frequent among nosocomially acquired cases. Two clones related to the paediatric clone ST5-IV accounted for 71% of the iso-
lates; EMRSA-16 has emerged in two different geographical areas. Only one isolate belonged to the formerly predominant Iberian clone.
The three CA isolates were related to the USA300 clone. SCCmec type IV was the most frequent type in nosocomial and HCA
isolates. The epidemiology of MRSA has changed in Spain; outpatients with previous healthcare contact represent a very important
reservoir of MRSA, and community isolates are emerging.
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Methicillin-resistant Staphyloccocus aureus (MRSA) is one of
the most important healthcare-associated (HCA) pathogens
worldwide [1,2]. The proportion of nosocomial infections
caused by MRSA continues to increase in most countries,
although with substantial variations [3–5].
Some signiﬁcant changes in the epidemiology of MRSA
have occurred during the last decade. Although the number
of infections due to HCA MRSA in non-hospitalized patients
is increasing [6], there are scarce data on the real burden of
HCA MRSA in outpatients. Also, a shift in the predominance
of HCA MRSA clones has been noted in some areas [7].
However, most studies have been performed in speciﬁc units
or hospitals, or lack information about the patients. Finally,
MRSA has recently emerged as a relevant community patho-
gen in several countries [8], but only anecdotal cases have
been reported in Spain so far [9,10].
The objectives of this study were to investigate the clinical
and molecular epidemiology of MRSA in a large sample of
Spanish hospitals, to provide comprehensive information on
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the burden of MRSA as a pathogen in non-hospitalized
patients, and to analyse the clinical features of nosocomial
and HCA MRSA infections.
Materials and Methods
Site
This study is part of the GEIH/GEMARA/REIPI MRSA 2003
project, which was aimed at investigating the epidemiological,
microbiological, clinical and prognostic features of MRSA
in Spain. The project also included a survey regarding the
control measures for MRSA in Spanish hospitals, which has
been published elsewhere [11]. Sixty-six hospitals, providing
healthcare to >16 million people, participated in the study.
Among them, 16 (24%) have <200 beds, 23 (35%) have
200–499 beds, and 27 (41%) have >500 beds; 36 (54%) are
tertiary centres, 23 (35%) are community centres, and seven
(11%) are private hospitals.
Design
A prospective cohort study, including all new patients from
whom MRSA was isolated from any clinical sample during
the month of June 2003 in the participating hospitals, was
performed. The microbiology records were reviewed to
avoid the inclusion of patients previously colonized or
infected with MRSA; patients from whom MRSA was isolated
during the previous 2 years were excluded. As surveillance
policies differ from hospital to hospital, patients who yielded
only MRSA-positive surveillance samples were excluded.
Variables and deﬁnitions
For each patient, the following data were recorded: age, gen-
der, hospitalization, previous healthcare contact, ward, type
and severity of underlying diseases (according to the McCabe
classiﬁcation) [12], invasive procedures, and antimicrobial use
during the preceding 2 months. Also, the presence of infec-
tion due to MRSA and the type of infection (both assessed
according to CDC criteria) [13], the presence of sepsis,
severe sepsis, or septic shock [14], antimicrobial treatment
and outcome were prospectively assessed. Patients were fol-
lowed for 30 days, or until discharge or death if it occurred
within 30 days.
MRSA acquisition was initially classiﬁed according to
epidemiological criteria. Thus, MRSA was considered to be
nosocomially acquired if isolated >48 h after admission of
the patient. In all other cases, MRSA was considered to be
HCA, i.e. if during the previous year any of the following
applied: admission for >2 days to a hospital, nursing home,
or other healthcare facility, surgery, dialysis, specialized home
care, visit at day hospitals, or permanent indwelling cathe-
ters. Also, MRSA in healthcare workers was considered to
be HCA. If none of the above applied, MRSA was considered
to be community-acquired (CA) [15]. Epidemiological criteria
were further assessed by analysing the microbiological fea-
tures of the isolates [15]. The project was approved by the
local ethic committees.
Microbiological studies
The ﬁrst isolate from each patient was sent to Hospital Uni-
versitario de Bellvitge, Barcelona, where identiﬁcation was
conﬁrmed by standard methods, and the presence of the
mecA gene was determined by PCR [16]. Susceptibility test-
ing was performed using the disk diffusion method according
to the CLSI criteria [17]. Inducible resistance to clindamycin
was detected by placing erythromycin and clindamycin disks
15–20 mm apart (D-zone test). MICs of mupirocin for resis-
tant strains were determined by Etest (AB biodisk, Solna,
Sweden). Heteroresistance to glycopeptides was screened
for on brain–heart infusion agar plates containing vancomycin
(6 mg/L) [18], using ATCC 700699 (Mu50) as a control
strain [19]. All MRSA isolates were classiﬁed according to
their resistance patterns (RPs), considering their resistance
to non-b-lactam antibiotics.
Genotyping was performed by macrorestriction analysis of
SmaI-digested DNA using pulsed-ﬁeld gel electrophoresis
(PFGE). PFGE was carried out for 23 h at 6 V/cm and 14C,
with pulses ranging from 1 to 30 s. PFGE patterns were
interpreted according to the criteria of Tenover et al. [20].
They were compared with those of the pandemic clones
EMRSA-15, EMRSA-16 [21], ATCC BAA-44 (Iberian clone)
[22], and ATCC BAA-42 (paediatric clone) [23]. Panton–
Valentine leukocidin genes were screened for with PCR [24].
Multilocus sequence typing and characterization of the staph-
ylococcal chromosomal cassette mec (SCCmec) were per-
formed for representative strains [25,26].
Statistical analysis
Nosocomial rates were calculated as the number of new
nosocomial MRSA cases per 100 admissions and 1000 inpa-
tient-days. The participating hospitals were required to indi-
cate the number of all new patients from whom S. aureus
had been isolated from clinical samples during the study per-
iod, in order to calculate the proportion of MRSA. Popula-
tion-based incidence rates were determined only in basic
health areas in which all hospitals participated in the study;
they were calculated as the number of new cases per
100 000 population-months. The assigned population for
each area during 2003 was used for the denominators. Qual-
itative variables were compared using the chi-squared test,
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and quantitative variables using Student’s t-test or the Mann–
Whitney U-test, as appropriate. The correlation between




During the study period, there were 370 new cases of colo-
nization or infection with MRSA in 59 of the 64 participating
hospitals/areas (92%); the ﬁve hospitals without MRSA cases
were community hospitals with <200 beds. The ﬁrst samples
yielding MRSA from the included patients were wound/ulcer
exudates in 179 cases (48%), respiratory tract samples in 75
cases (20%), blood culture samples in 50 cases(14%), urine in
31 cases (8%), catheter-tip samples in ten cases(3%), joint
ﬂuid in four cases(1%), and others in 21 cases(6%).
MRSA was considered to be nosocomially acquired in 202
patients (55%), HCA in 139 patients (38%), and CA in three
patients (<1%); the mode of acquisition was uncertain in 26
outpatients (7%), because the previous healthcare contact
could not be adequately assessed. The range in the number
of cases per hospital was 0–23. Population-based rates could
be calculated for 39 basic health areas. The pooled incidence
rate of MRSA colonization or infection was 2.31 cases/
100 000 population-months, and that of MRSA bacteraemia
was 0.23. Nosocomial rates are shown in Table 1. Nosoco-
mial rates would have been approximately two-fold higher if
all HCA MRSA cases had been included in the numerators
(0.34 cases per 100 admissions or 0.47 per 1000 patient-
days). The pooled percentage of patients with nosocomial
MRSA among patients with nosocomial S. aureus was 20.2%,
and the median percentage was 20.0% (interquartile range:
4.1–28.0%). We found no signiﬁcant differences between
hospitals with 200–499 beds and those with ‡500 beds in
terms of nosocomial incidence rates (median number of
cases/1000 hospital-days, 0.15 vs. 0.21, p 0.1) or percentage
of MRSA (median, 19% vs. 20%, p 0.4).
Epidemiology and clinical features
Owing to insufﬁcient data, we excluded the 26 cases with
uncertainty about the MRSA acquisition; thus, the analysis
includes 344 patients. Among the 202 nosocomially acquired
cases, 40 (20%) were admitted to an intensive-care unit. The
median previous hospital stay of nosocomial cases was
10 days (range, 3–330). Among the 139 patients with HCA
MRSA, 40 (29%) were in nursing homes or long-term-care
facilities, 63 (45%) had been previously admitted (one was a
nursing home resident), 39 (28%) received care in specialized
home-care programmes or day hospitals, six (4%) received
haemodialysis, and one was a healthcare worker. The predis-
posing features of the 341 patients with nosocomial MRSA
and HCA MRSA are shown in Table 2. Among the three
community-acquired cases, two patients were <30 years old
and had no comorbidities.
MRSA was considered to be causing an infection in 138
(68%) patients with nosocomial MRSA and in 90 (65%)
TABLE 1. Rates of nosocomial colonization/infection due to













Global 0.15 0.21 0.11 (0.04–0.20) 0.16 (0.06–0.27)
Medical
wards
0.18 0.19 0.19 (0–0.30) 0.15 (0–0.30)
Surgical
wards
0.10 0.17 0 (0–0.18) 0 (0–0.24)
Intensive-
care units
0.65 1.18 0.06 (0–2.25) 0 (0–4.22)
Patients with healthcare-associated MRSA were not included in the numerators.
TABLE 2. Predisposing factors of patients with nosocomial









(n = 139) pa
Male gender 199 (58) 131 (65) 75 (54) 0.04
Median age in years
(range)




Non-fatal 215 (63) 125 (62) 90 (65)
Ultimately fatal 96 (28) 41 (20) 41 (29)
Rapidly fatal 30 (9) 22 (11) 8 (6)
Diabetes mellitus 100 (29) 61 (30) 39 (28) 0.6
Neoplasia 75 (22) 52 (26) 23 (16) 0.04
Chronic pulmonary
disease
71 (21) 41 (20) 29 (21) 0.9
Peripheral vascular
disease
59 (17) 25 (12) 34 (24) 0.004
Chronic renal
insufﬁciency
36 (11) 19 (9) 17 (12) 0.4
Liver cirrhosis 19 (6) 14 (7) 5 (4) 0.1
Pressure ulcer 43 (13) 12 (6) 11 (8) 0.4
Intravascular catheter 192 (56) 140 (69) 52 (37) <0.001
Urinary catheter 101 (30) 72 (36) 29 (21) 0.003
Mechanical ventilation 37 (11) 34 (17) 0 <0.001
Surgery 107 (31) 82 (41) 25 (18) <0.001
Previous antimicrobials 241 (71) 157 (78) 86 (62) 0.001
Penicillins 109 (32) 97 (48) 61 (44) 0.4
Cephalosporins 70 (21) 69 (34) 29 (21) 0.007
Fluoroquinolones 110 (32) 93 (46) 68 (49) 0.6
Data are expressed as no. of cases (%), except where indicated.
aChi-squared test except where indicated.
bMann–Whitney U-test.
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patients with HCA MRSA (p 0.5). Clinical and prognostic fea-
tures of patients with infection due to nosocomial and HCA
MRSA are shown in Table 3. There were no differences with
respect to frequency or type of infection, bacteraemia or
mortality among isolates from the most frequent clonal
groups. The three patients with CA MRSA had cellulitis and
were cured.
Microbiological results
All 370 isolates were analysed. Susceptibility data are
shown in Table 4. The macrolide–lincosamide–streptogramin B
(MLSB) resistance phenotype was found in 46% of the strains,
whereas selective resistance to macrolides and streptogramin
B (MSB phenotype) was found in 29%. Among the 72
mupirocin-resistant strains, 17 were isolated in a single hospi-
tal, 50 showed MICs >512 mg/L, and ten were clonally
related. No resistance or heteroresistance to glycopeptides
was detected in any strain. Although 26 RPs were found, 247
isolates (67%) belonged to one of the four predominant RPs
(Table 5). The three CA isolates were susceptible to all non-
b-lactam antibiotics.
PFGE analysis of nosocomial and HCA MRSA revealed 33
different types. There were two predominant clonal groups,
present in 45 hospitals: clonal group Q (138 isolates, 37%),
and clonal group P (125 isolates, 34%). Both clonal groups
were present at similar frequencies in nosocomial and HCA
isolates, or in those of uncertain origin (Table 4). The 12
selected strains from subtypes of clones Q and P studied by
multilocus sequence typing belonged to clonal complex 5:
ST5 (one strain) or their single-locus variants ST125 (eight
strains) and ST146 (three strains). Thirty-ﬁve clonally related
strains (clone BA, 10%) from 13 hospitals belonged to the
EMRSA-16 (ST36) clone; 31 of these isolates came from hos-
pitals in Galicia (22 isolates) and the Canary Islands (nine).
Also, seven strains (six from a single hospital in Majorca)
belonged to the EMRSA-15 (ST22) clone. Only one strain
belonged to the formerly predominant Iberian clone (ST247).
There were no differences in predisposing factors, clinical
features or prognosis among patients with the most frequent
clones.
The SCCmec type was studied in 80 isolates, including 22
clone P isolates, 22 clone Q isolates, six clone BA isolates,
and one representative of every other PFGE type. In two
isolates, the SCCmec type could not be determined; 18/22
and 17/22 clone P and clone Q isolates (82% and 77%,
respectively) carried SCCmec type IV, and ﬁve or six
clone BA (ST36) isolates carried SCCmec type II. The
SCCmec types as related to the mode of MRSA acquisition
are shown in Table 4.
PVL gene detection was performed in 104 selected cases,
including CA cases, cases of uncertain mode of acquisition,
cases of soft tissue infections, and most susceptible isolates;
three of them (two CA MRSA and one HCA MRSA) were PVL
gene-positive. The PVL gene-positive strains were isolated in
two hospitals in Barcelona, belonged to ST8 (which was not
found in other isolates), and harboured SCCmec type IV.
Discussion
In this prospective multicentre study performed in Spain,
some signiﬁcant changes in MRSA epidemiology were
observed with regard to older data. MRSA was found to be
nosocomially acquired in only 55% of the cases, and the rest
of the MRSA acquisition occurred in outpatients, in whom
MRSA was considered to be HCA, with the exception of
three cases of CA MRSA. Approximately 70% of the isolates
belonged to two PFGE groups, and SCCmec type IV was pre-
dominant.
To our knowledge, this is the ﬁrst multicentre study to
integrate multiple aspects of MRSA epidemiology. The study
was performed in 2003; no signiﬁcant changes in the per-
centage of MRSA [6] or circulating MRSA clones seem to
have occurred in Spain since then (47th Interscience Confer-
ence on Antimicrobial Agents and Chemotherapy, Chicago,
2007, Abstract C2-148). The duration of the study period
(1 month) is the main limitation for the estimation of inci-
TABLE 3. Clinical features and outcome of patients with
infection due to nosocomial and healthcare-associated
methicillin-resistant Staphylococcus aureus (patients without







(n = 90) pa
Type of infectionb
Skin and soft tissue 61 (44) 43 (48) 0.5
Respiratory tract 31 (22) 11 (12) 0.05
Urinary tract 7 (5) 13 (14) 0.01
Bone and joints 6 (4) 7 (8) 0.2
Catheter-related infection 19 (14) 3 (3) 0.009
Primary bacteraemia 7 (5) 4 (4) 0.8
Intra-abdominal 5 (4) 2 (2) 0.5
Miscellaneous 2 (1) 6 (7) 0.06
Bloodstream infection
(primary or secondary)
42 (30) 15 (17) 0.01
Surgical site infections 46 (33) 11 (12) <0.001
Crude mortalityc 33 (24) 11 (12) 0.02
Infection-related mortalityd 17 (12) 9 (10) 0.5
Data are expressed as no. of cases (%) except where indicated.
aChi-squared test.
bIncisional surgical infections are classiﬁed as skin and soft tissue infections.
Organ/space surgical site infections are classiﬁed according to the organ
affected.
cIncludes all deaths that occurred during follow-up.
dIncludes all deaths that occurred as a direct consequence of MRSA infection
without another plausible cause, as determined by the investigators.
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dence rates, which should be considered here to be mini-
mum rates. However, a longer study period would have
made the inclusion of precise epidemiological and clinical
data very difﬁcult.
The percentage of MRSA found in this study (20%) is
lower than those found in some recent prevalence studies
performed in Spain (29–41%) [6,27]. Apart from the fact that
one of these studies included patients identiﬁed as MRSA-
positive by means of active surveillance [6], prevalence stud-
ies may overestimate the real percentage of MRSA, as
patients colonized or infected by this organism have a longer
hospital stay and are more frequently tested than patients
with methicillin-susceptible S. aureus [2], thus increasing the
probability of their being included in prevalence studies. In
fact, the present data are similar to those of other incidence
studies performed in Spain (with MRSA rates ranging from
22% to 28%) [28,29]. With regard to population-based
MRSA rates, data are scarce. Morgan et al. found 92.4 cases
of MRSA colonization or infection (including cases detected
by active surveillance) and 5.2 cases of MRSA bacteraemia
per 100 000 population/year during 1996 in Wales [30]. The
extrapolated population-based rates per year of the present
study would be 27.7 and 2.7, respectively. This is in agree-
ment with the fact that percentages of MRSA among
S. aureus are much lower in Spain than in the UK [5]. One
of the main ﬁndings of this study is that only 55% of the
MRSA cases were nosocomially acquired, and that almost all
the rest were outpatients with previous healthcare contact.
This emphasizes the importance of chronic colonization after
MRSA acquisition in healthcare facilities. As characterizing
the epidemiology of MRSA in outpatients is difﬁcult, previous
healthcare contact could not be adequately assessed in 7% of
the cases; however, isolates from outpatients were clonally
related to HCA and nosocomial isolates. Charberny et al.
[31] found a similar proportion of non-nosocomial cases in
Germany. Thus, approximately half of the HCA MRSA clini-
TABLE 4. Resistance to selected
antimicrobial agents, distribution
of molecular types (pulsed-ﬁeld gel
electrophoresis (PFGE)), SCCmec
types, and presence of Panton–
Valentine leukocidin (PVL) genes
among methicillin-resistant Staphy-
lococcus aureus isolates according













Erythromycin 278 (75) 153 (76) 111 (79) 0 15 (58)
Clindamycin 169 (46) 106 (53) 60 (43) 0 2 (8)
Gentamicin 90 (24) 56 (28) 30 (22) 0 3 (12)
Tobramycin 320 (87) 178 (88) 120 (86) 0 21 (81)
Rifampin 5 (1) 1 (<1) 4 (3) 0 0
Ciproﬂoxacin 363 (98) 199 (99) 138 (99) 0 26 (100)
Trimethoprim–
sulphamethoxazole
6 (2) 2 (1) 3 (2) 0 1 (4)
Tetracycline 3 (1) 1 (<1) 2 (1) 0 0
Chloramphenicol 39 (11) 22 (11) 14 (10) 0 3 (12)
Mupirocin 72 (19) 38 (19) 20 (14) 0 5 (19)
Vancomycin 0 0 0 0 0
Quinupristin–
dalfopristin
0 0 0 0 0
Linezolid 0 0 0 0 0
PFGE
Clone Q (CC5) 138 (37) 75 (37) 55 (39) 0 8 (31)
Clone P (CC5) 125 (34) 65 (32) 47 (34) 0 13 (50)
Clone BA (ST36) 35 (9) 23 (12) 11 (8) 0 0
Other clones 73 (20) 39 (19) 26 (19) 3 (100) 5 (19)
SCCmec type n = 78 n = 40 n = 26 n = 3 n = 9
I 18 (23) 11 (28) 5 (19) 1 (33) 1 (11)
II 10 (13) 8 (20) 2 (8) 0 0
III 1 (1) 1 (2) 0 0 0
IV 49 (63) 20 (50) 19 (73) 2 (66) 8 (89)
PVL genes n = 104 n = 20 n = 55 n = 3 n = 26
Positive 3 0 1 2 0
HCA, healthcare-associated; CA, community-acquired.
SCCmec type and presence of PVL genes were determined in representative isolates (see text). Data are expressed
as no. of isolates (percentage).
TABLE 5. Distribution of resistance patterns of methicillin-
resistant Staphylococcus aureus strains according to geno-
types
Resistance
patterns Clone Q Clone P EMRSA-16
Other
clones Total
Er, Cl, Gen, Tob, Cip 14 (10) 17 (14) 6 (17) 18 (25) 55 (15)
Er, Cl, Tob, Cip 16 (12) 33 (26) 20 (57) 9 (13) 78 (21)
Er, Tob, Cip 43 (31) 13 (10) 1 (3) 8 (11) 65 (18)
Tob, Cip 13 (9) 30 (24) 0 6 (8) 49 (13)
Other patterns 52 (38) 32 (25) 8 (23) 31 (43) 123 (33)
Total 138 (100) 125 (100) 35 (100) 72 (100) 370 (100)
Data are expressed as no. of isolates (%).
Er, erythromycin; Cl, clindamycin; Gen, gentamicin; Tob, tobramycin; Cip, cipro-
ﬂoxacin.
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cal cases are now being diagnosed in outpatients. These data
show that the determination of nosocomial rates is insufﬁ-
cient to provide an idea of the global epidemiology of HCA
MRSA and of the enormous reservoir of HCA MRSA in out-
patients, and they support the need for targeted active sur-
veillance of patients at admission [32]. Regarding the
nosocomial rates, this study also shows that if all HCA cases
are included in the numerators, nosocomial rates may be
considerably overestimated. Thus, a consensus for a precise
deﬁnition of MRSA rates is necessary.
There are only scarce data in the literature concerning
the predisposing factors and clinical features of outpatients
with HCA MRSA. We found few differences in intrinsic fea-
tures between patients with nosocomial and HCA MRSA:
the latter were older and suffered more frequently from
peripheral vascular disease. Crude mortality was higher
among patients with nosocomial infection, but infection-
related mortality was similar in both groups.
With regard to the antimicrobial susceptibility data, no
correlation was found between PFGE genotypes and RPs, as
previously described [29]. The susceptibility data and molecu-
lar typing results conﬁrm a shift from some multidrug-resistant
clones (particularly the Iberian clone) to more susceptible
clones [7,29,33,34]. More than 70% of the isolates analysed
here belonged to two clonal groups; these dominant geno-
types belong to a common clonal complex (CC5) that may
have evolved from the paediatric clone ST5-IV [26]. Isolates of
this clonal complex emerged in Spain in 1996 [34] and are
now predominant. Other international clones detected in this
study were EMRSA-16 (ST36) and EMRSA-15 (ST22); EMRSA-
16 had been rare in Spain [34], except in the Canary Islands
[7], but our study documents its spread also in Galicia.
EMRSA-15 was found almost exclusively in one hospital in
Majorca. It is of interest that SCCmec type IV is not a good
marker for community isolates in Spain, as it was the most fre-
quent type among HCA and nosocomial isolates. Another
interesting ﬁnding was the remarkably low number of PVL
gene-positive strains in this study; their features suggest the
initial spread of a clone with genetic traits related to those of
the USA300 clone (ST8-IV). Infections due to CA MRSA have
been recently described in Madrid [9] and Barcelona [10].
In conclusion, the vast reservoir of a few predominant
HCA MRSA clones in outpatients (mainly patients with
previous hospital admission and residents in long-term-care
facilities) in Spain represents a challenge for infection con-
trol. Also, continuous surveillance and action are needed
to control the dissemination of some emergent interna-
tional HCA and CA clones. In this context, a consensus
document concerning MRSA control has recently been
published [35].
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Appendix
Participants in the MRSA 2003 GEIH/GEMARA/REIPI project:
J. A´lvarez, M. Alcalde, C. Zamorano (Hosp. de Cieza, Murcia);
G. Sauca, L. Force, E. Martı´nez (Hosp. de Mataro´, Barce-
lona);
E. Hidalgo, E. Mata, J. S. Rubio (Hosp. de Jove, Gijo´n,
Asturias);
A. Bordes, M. A. Figuerola, B. Lafarga (Hosp. Dr Negrı´n,
Las Palmas, Gran Canaria)
A. Leturia (Hosp. Nal. de Paraple´jicos, Toledo);
F. Calvo, J. Pe´rez, J. L. Sa´nchez (Hosp. de Santa Marina,
Bilbao);
J. Bla´zquez, C. Domı´nguez, C. Mirete, M. Gea, M. Bermu´dez
(Hosp. de S. Vicente, Alicante);
T. Alarco´n, C. Cuevas, N. Carrasco, J. Jimeno (Hosp. Univ.
Princesa, Madrid);
A. Canut, A. Labora, J. L. Novales, I. Orio (Hosp. Santiago
Apo´stol, Vitoria);
J. Serralta, D. Arzua (Clı´nica Benidorm, Alicante);
G. Esteban, B. Ferna´ndez, M. D. Dı´az (Hosp. Sta. Marı´a
Mai, Ourense);
R. Carranza, D. Tena, J. R. Barbera´ (Hosp. Mancha Centro,
Alca´zar de San Juan, Toledo);
A. Asensio, J. Lobera, T. Marco, A. Ramos (Hosp. Pta. de
Hierro, Madrid);
M. L. Garcı´a, M. D. Miguel (Hosp. Cabuen˜es, Asturias);
F. Chaves, F. Jae´n, M. Lizasoain, M. I. Sanz (Hosp. 12 de
Octubre, Madrid);
E. Cercenado, B. Padilla, F. Grande (Hosp. Gregorio Mara-
n˜o´n, Madrid);
M. D. Rodrı´guez, J. F. Garcı´a, M. V. Lorenzo (Hosp. P.
Novoa Santos, Ferrol, A Corun˜a)
A. Yagu¨e, A. Cabrera, J. Gregori, J. Salinas (Hosp. Vega
Baja, Orihuela, Alicante);
M. Elı´a, J. M. Ramos, A. M. Haro (Hosp. de Elche, Alicante);
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M. T. Bastida, R. Porro´n, F. Nonell (Hosp. Esperit Sant,
Santa Coloma de Gramanet, Barcelona);
T. Delgado, M. de Frutos, I. Montesinos (Hosp. Univ. de
Canarias, Tenerife);
M. Xercavins, N. Juan, M. Riera, N. Freixas (Hosp. M. de
Terrassa, Barcelona);
M. A. Sepu´lveda, C. Go´mez (Hosp. V. de la Salud,
Toledo);
P. A´lvarez, R. Ojeu, F. Vazquez, J. Paz (Hosp. de Pontevedra);
J. A. Jime´nez, E. Lavin˜eta (Policlı´nica Guipu´zcoa, San Sebastia´n);
R. M. Ferreruela, A. Vin˜uales, J. M. Tenias (Hosp. L.
Alcanyı´s, Xa´tiva, Valencia);
A. Zapata, J. L. de Francisco (Hosp. de Jerez de la
Frontera);
A. Moreno, M. C. Dura´n, N. Batista (Hosp. Candelaria,
Santa Cruz, Tenerife);
C. Martı´nez, M. J. Gallego, C. Amador (Hosp. Marina Bai-
xa, Villajoyosa, Alicante);
F. J. Noguera, D. Panizo, E. Melian (Hosp. Gral. de Lanza-
rote);
A. Fleites, A. Moreno (Hosp. Gral. de Asturias, Oviedo);
F. Pardo, M. L. Pe´rez, E. Carballo (Hosp. de Santiago de
Compostela);
M. A. Gasos, A. Pe´rez, M. Vidal (Hosp. S. Joan de De´u,
Martorell, Barcelona);
J. R. Herna´ndez, L. Garcı´a (Hosp. Macarena, Sevilla);
A. Coloma, F. Navarro, J. Barrio, P. Coll (Hosp. S. Pau,
Barcelona);
M. Bolan˜os, E. A´lvarez, M. Herna´ndez, J. Molina (Hosp.
Insular, Gran Canaria);
P. Garcı´a, B. R. Blazquez, M. Cal (Hosp. de Getafe,
Madrid);
S. Giner, P. Garcı´a, N. Tolosa (Hosp. Dr Moliner, Serra,
Valencia);
A. Caldero´n (Hosp. de Badalona);
C. Arana (Hosp. V. Victoria, Ma´laga);
F. Ulloa, E. Pazos, M. Maresclot (Hosp. N. Pen˜a, Vigo);
J. E. Corzo, J. L. Garcı´a (Hosp. Valme, Sevilla);
J. L. Herna´ndez, K. Aguirrebengoa, J. M. Herna´ndez (Hosp.
Cruces, Vizcaya);
M. Motje´, J. de Batlle, D. Garcı´a, L. Gavalda´ (Hosp. Dr J.
Trueta, Gerona);
M. A´lvarez, C. Potel (Hosp. Cies, Vigo);
R. Escoms, J. Prat, C. Gonza´lez, M. Pinazo (Hosp. de Sag-
unto, Valencia);
M. Canals, D. Mariscal, N. Garcı´a (Hosp. Parc Tauli, Saba-
dell, Barcelona);
A. Andreu, M. Campins, N. Larrosa (Hosp. Vall d’Hebron,
Barcelona);
J. M. Cisneros, A. C. Llanos (Hosp. V. Rocı´o, Sevilla);
J. L. Pe´rez, A. Oliver, M. Pen˜aranda, C. Juan, E. Ruiz
(Hosp. Son Dureta, Palma de Mallorca);
V. Pintado, R. Canto´n, J. Oliva, L. Garcı´a, F. Grill (Hosp.
Ramo´n y Cajal, Madrid);
J. Dı´az, V. Ca´rcava (Hosp. Oriente, Arriendas, Asturias);
C. Garcı´a, J. Cucurull (Hosp. Figueres, Gerona);
D. Sousa, G. Bou (Hosp. J. Canalejo, La Corun˜a);
E. Limo´n (Hosp. Bellvitge, Barcelona);
J. Cuquet, C. Martı´, M. D. Navarro (Hosp. de Granollers,
Barcelona);
P. Berdonces, J. Mayo (Hosp. de Galdakao, Vizkaya);
M. Sierra, M. Vaque, M. Calsina (Hosp. SCIAS, Barcelona);
S. Illescas, A. Lo´pez (Hosp. V. Altagracia, Manzanares,
Ciudad Real);
A. Herna´ndez, M. L. Abella´n, A. Garcı´a (Hosp. S. Jaume,
Calella, Barcelona);
A. Garcı´a, C. Galle´s (Hosp. de la Selva, Blanes, Gerona);
M. Salvado´ (Hosp. del Mar, Barcelona);
L. Matas, N. Sopena, M. Caraballo (Hosp. G. Trias i Pujol,
Badalona);
A. Coira, J. Varela (Hosp. Calde, Lugo);
M. Cuenca, A. Guerrero (Hosp. de la Ribera, Alcira);
J. P. Horcajada, F. Marco, M. Zaragoza, M. Piazuelo, J. A.
Martı´nez (Hosp. Clinic, Barcelona).
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